Monthly
US$200
Billed every month
罗沙司他胶囊
Companies, stages and changes, with each record available on this page.
No changes recorded by this site in the last 90 days
Complete CDE snapshot: 2026/11/10 07:27
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders28View records ↓
Under-review filings17View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers51View records ↓
API companies with A status29View records ↓
Chemical-drug catalogue
Loaded records: 28 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 27 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 浙江贝得药业有限公司 | 浙江贝得药业有限公司 | 国药准字H20264913 | 2026/06/23 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江百代医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20264906 | 2026/06/23 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江贝得药业有限公司 | 浙江贝得药业有限公司 | 国药准字H20264912 | 2026/06/23 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江百代医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20264907 | 2026/06/23 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海医药集团青岛国风药业股份有限公司 | 上海医药集团青岛国风药业股份有限公司 | 国药准字H20264644 | 2026/06/03 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海医药集团青岛国风药业股份有限公司 | 上海医药集团青岛国风药业股份有限公司 | 国药准字H20264643 | 2026/06/03 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江高跖医药科技股份有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20264529 | 2026/05/27 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江高跖医药科技股份有限公司 | 宁波美诺华天康药业有限公司 | 国药准字H20264528 | 2026/05/27 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽省先锋制药有限公司 | 安徽省先锋制药有限公司 | 国药准字H20264133 | 2026/04/21 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽省先锋制药有限公司 | 安徽省先锋制药有限公司 | 国药准字H20264132 | 2026/04/21 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西迪赛诺医药集团有限公司 | 江苏诚康药业有限公司 | 国药准字H20264034 | 2026/04/14 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南明瑞制药股份有限公司 | 湖南明瑞制药股份有限公司 | 国药准字H20263132 | 2026/01/14 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆煜洋药业有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20256140 | 2025/12/03 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南埃威格林医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20255835 | 2025/11/04 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南埃威格林医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20255834 | 2025/11/04 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 郑州德迈药业有限公司 | 浙江华润三九众益制药有限公司 | 国药准字H20255014 | 2025/07/29 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 郑州德迈药业有限公司 | 浙江华润三九众益制药有限公司 | 国药准字H20255015 | 2025/07/29 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 昆山龙灯瑞迪制药有限公司 | 昆山龙灯瑞迪制药有限公司 | 国药准字H20255033 | 2025/07/29 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 昆山龙灯瑞迪制药有限公司 | 昆山龙灯瑞迪制药有限公司 | 国药准字H20255034 | 2025/07/29 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆圣华曦药业股份有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20254104 | 2025/05/13 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆圣华曦药业股份有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20254103 | 2025/05/13 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川国为制药有限公司 | 四川国为制药有限公司 | 国药准字H20254048 | 2025/04/30 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川国为制药有限公司 | 四川国为制药有限公司 | 国药准字H20254047 | 2025/04/30 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新时代药业有限公司 | 山东新时代药业有限公司 | 国药准字H20253816 | 2025/04/08 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东新时代药业有限公司 | 山东新时代药业有限公司 | 国药准字H20253815 | 2025/04/08 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都青山利康药业股份有限公司 | 四川科伦药业股份有限公司 | 国药准字H20253621 | 2025/03/11 | 50mg | Not stated by source | CDE |
| 海口市制药厂有限公司 | 海口市制药厂有限公司 | 国药准字H20253575 | 2025/03/11 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海口市制药厂有限公司 | 海口市制药厂有限公司 | 国药准字H20253574 | 2025/03/11 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江尖峰药业有限公司 | 浙江尖峰药业有限公司 | 国药准字H20253546 | 2025/03/04 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江尖峰药业有限公司 | 浙江尖峰药业有限公司 | 国药准字H20253545 | 2025/03/04 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南先施制药有限公司 | 湖南九典制药股份有限公司 | 国药准字H20253332 | 2025/02/08 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南先施制药有限公司 | 湖南九典制药股份有限公司 | 国药准字H20253333 | 2025/02/08 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏万邦生化医药集团有限责任公司 | 江苏万邦生化医药集团有限责任公司 | 国药准字H20253321 | 2025/01/24 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏万邦生化医药集团有限责任公司 | 江苏万邦生化医药集团有限责任公司 | 国药准字H20253322 | 2025/01/24 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 哈尔滨三联药业股份有限公司 | 兰西哈三联制药有限公司 | 国药准字H20253086 | 2025/01/08 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 哈尔滨三联药业股份有限公司 | 兰西哈三联制药有限公司 | 国药准字H20253087 | 2025/01/08 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州康臣药业有限公司 | 成都倍特药业股份有限公司 | 国药准字H20253093 | 2025/01/08 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20253115 | 2025/01/08 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京福元医药股份有限公司 | 北京福元医药股份有限公司 | 国药准字H20253116 | 2025/01/08 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 济川药业集团有限公司 | 济川药业集团有限公司 | 国药准字H20253058 | 2025/01/02 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 济川药业集团有限公司 | 济川药业集团有限公司 | 国药准字H20253059 | 2025/01/02 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 齐鲁制药有限公司 | 齐鲁制药有限公司 | 国药准字H20249824 | 2024/12/25 | 50mg | Not stated by source | CDE |
| 齐鲁制药有限公司 | 齐鲁制药有限公司 | 国药准字H20249825 | 2024/12/25 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州康臣药业有限公司 | 成都倍特药业股份有限公司 | 国药准字H20249771 | 2024/12/25 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南明瑞制药股份有限公司 | 湖南明瑞制药股份有限公司 | 国药准字H20249733 | 2024/12/17 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20249731 | 2024/12/17 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20249732 | 2024/12/17 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西山香药业有限公司 | 江西山香药业有限公司 | 国药准字H20249729 | 2024/12/17 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西山香药业有限公司 | 江西山香药业有限公司 | 国药准字H20249730 | 2024/12/17 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20244417 | 2024/07/09 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 成都倍特药业股份有限公司 | 国药准字H20244418 | 2024/07/09 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团中诺药业（石家庄）有限公司 | 石药集团中诺药业（石家庄）有限公司 | 国药准字H20244185 | 2024/06/28 | 20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团中诺药业（石家庄）有限公司 | 石药集团中诺药业（石家庄）有限公司 | 国药准字H20244184 | 2024/06/28 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 51 distinct approval numbers and 27 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京福元医药股份有限公司 | 国药准字H20253116 | 20mg | Category B (乙) | XB03XAL373E001010100177 | NHSA |
| 广州康臣药业有限公司 | 国药准字H20249771 | 50mg | Category B (乙) | XB03XAL373E001010100400 | NHSA |
| 济川药业集团有限公司 | 国药准字H20253058 | 20mg | Category B (乙) | XB03XAL373E001010101453 | NHSA |
| 昆山龙灯瑞迪制药有限公司 | 国药准字H20255033 | 20mg | Category B (乙) | XB03XAL373E001010101533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20249731 | 50mg | Category B (乙) | XB03XAL373E001010101606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20253321 | 20mg | Category B (乙) | XB03XAL373E001010101729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20244417 | 20mg | Category B (乙) | XB03XAL373E001010102013 | NHSA |
| 成都青山利康药业股份有限公司 | 国药准字H20253621 | 50mg | Category B (乙) | XB03XAL373E001010102053 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20244184 | 50mg | Category B (乙) | XB03XAL373E001010102777 | NHSA |
| 哈尔滨三联药业股份有限公司 | 国药准字H20253086 | 20mg | Category B (乙) | XB03XAL373E001010103662 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20249824 | 50mg | Category B (乙) | XB03XAL373E001010104021 | NHSA |
| 上海医药集团青岛国风药业股份有限公司 | 国药准字H20264643 | 20mg | Category B (乙) | XB03XAL373E001010104034 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253815 | 20mg | Category B (乙) | XB03XAL373E001010104188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010104339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264912 | 50mg | Category B (乙) | XB03XAL373E001010104612 | NHSA |
| 浙江尖峰药业有限公司 | 国药准字H20253545 | 20mg | Category B (乙) | XB03XAL373E001010104655 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20249733 | 50mg | Category B (乙) | XB03XAL373E001010105001 | NHSA |
| 江西山香药业有限公司 | 国药准字H20249729 | 50mg | Category B (乙) | XB03XAL373E001010105345 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20253574 | 20mg | Category B (乙) | XB03XAL373E001010105758 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254103 | 20mg | Category B (乙) | XB03XAL373E001010109568 | NHSA |
| 珐博进(中国)医药技术开发有限公司 | 国药准字H20180023 | 20mg | Category B (乙) | XB03XAL373E001010180523 | NHSA |
| 四川国为制药有限公司 | 国药准字H20254048 | 50mg | Category B (乙) | XB03XAL373E001010180937 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253332 | 50mg | Category B (乙) | XB03XAL373E001010184106 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264528 | 20mg | Category B (乙) | XB03XAL373E001010184221 | NHSA |
| 湖南埃威格林医药科技有限公司 | 国药准字H20255834 | 50mg | Category B (乙) | XB03XAL373E001010184441 | NHSA |
| 郑州德迈药业有限公司 | 国药准字H20255014 | 50mg | Category B (乙) | XB03XAL373E001010184733 | NHSA |
| 江西迪赛诺医药集团有限公司 | 国药准字H20264034 | 50mg | Category B (乙) | XB03XAL373E001010185211 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253116 | 20mg | Category B (乙) | XB03XAL373E001010200177 | NHSA |
| 广州康臣药业有限公司 | 国药准字H20249771 | 50mg | Category B (乙) | XB03XAL373E001010200400 | NHSA |
| 昆山龙灯瑞迪制药有限公司 | 国药准字H20255033 | 20mg | Category B (乙) | XB03XAL373E001010201533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20249731 | 50mg | Category B (乙) | XB03XAL373E001010201606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20253321 | 20mg | Category B (乙) | XB03XAL373E001010201729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20244417 | 20mg | Category B (乙) | XB03XAL373E001010202013 | NHSA |
| 成都青山利康药业股份有限公司 | 国药准字H20253621 | 50mg | Category B (乙) | XB03XAL373E001010202053 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20244184 | 50mg | Category B (乙) | XB03XAL373E001010202777 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20249824 | 50mg | Category B (乙) | XB03XAL373E001010204021 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253815 | 20mg | Category B (乙) | XB03XAL373E001010204188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010204339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264912 | 50mg | Category B (乙) | XB03XAL373E001010204612 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20249733 | 50mg | Category B (乙) | XB03XAL373E001010205001 | NHSA |
| 江西山香药业有限公司 | 国药准字H20249729 | 50mg | Category B (乙) | XB03XAL373E001010205345 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254103 | 20mg | Category B (乙) | XB03XAL373E001010209568 | NHSA |
| 四川国为制药有限公司 | 国药准字H20254048 | 50mg | Category B (乙) | XB03XAL373E001010280937 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253332 | 50mg | Category B (乙) | XB03XAL373E001010284106 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264528 | 20mg | Category B (乙) | XB03XAL373E001010284221 | NHSA |
| 湖南埃威格林医药科技有限公司 | 国药准字H20255834 | 50mg | Category B (乙) | XB03XAL373E001010284441 | NHSA |
| 郑州德迈药业有限公司 | 国药准字H20255014 | 50mg | Category B (乙) | XB03XAL373E001010284733 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253116 | 20mg | Category B (乙) | XB03XAL373E001010300177 | NHSA |
| 广州康臣药业有限公司 | 国药准字H20249771 | 50mg | Category B (乙) | XB03XAL373E001010300400 | NHSA |
| 昆山龙灯瑞迪制药有限公司 | 国药准字H20255033 | 20mg | Category B (乙) | XB03XAL373E001010301533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20249731 | 50mg | Category B (乙) | XB03XAL373E001010301606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20253321 | 20mg | Category B (乙) | XB03XAL373E001010301729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20244417 | 20mg | Category B (乙) | XB03XAL373E001010302013 | NHSA |
| 成都青山利康药业股份有限公司 | 国药准字H20253621 | 50mg | Category B (乙) | XB03XAL373E001010302053 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20244184 | 50mg | Category B (乙) | XB03XAL373E001010302777 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253815 | 20mg | Category B (乙) | XB03XAL373E001010304188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010304339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264912 | 50mg | Category B (乙) | XB03XAL373E001010304612 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20249733 | 50mg | Category B (乙) | XB03XAL373E001010305001 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254103 | 20mg | Category B (乙) | XB03XAL373E001010309568 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253332 | 50mg | Category B (乙) | XB03XAL373E001010384106 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264528 | 20mg | Category B (乙) | XB03XAL373E001010384221 | NHSA |
| 湖南埃威格林医药科技有限公司 | 国药准字H20255834 | 50mg | Category B (乙) | XB03XAL373E001010384441 | NHSA |
| 郑州德迈药业有限公司 | 国药准字H20255014 | 50mg | Category B (乙) | XB03XAL373E001010384733 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253116 | 20mg | Category B (乙) | XB03XAL373E001010400177 | NHSA |
| 广州康臣药业有限公司 | 国药准字H20249771 | 50mg | Category B (乙) | XB03XAL373E001010400400 | NHSA |
| 昆山龙灯瑞迪制药有限公司 | 国药准字H20255033 | 20mg | Category B (乙) | XB03XAL373E001010401533 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20253321 | 20mg | Category B (乙) | XB03XAL373E001010401729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20244417 | 20mg | Category B (乙) | XB03XAL373E001010402013 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20244184 | 50mg | Category B (乙) | XB03XAL373E001010402777 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253815 | 20mg | Category B (乙) | XB03XAL373E001010404188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010404339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264912 | 50mg | Category B (乙) | XB03XAL373E001010404612 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20249733 | 50mg | Category B (乙) | XB03XAL373E001010405001 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254103 | 20mg | Category B (乙) | XB03XAL373E001010409568 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253332 | 50mg | Category B (乙) | XB03XAL373E001010484106 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264528 | 20mg | Category B (乙) | XB03XAL373E001010484221 | NHSA |
| 郑州德迈药业有限公司 | 国药准字H20255014 | 50mg | Category B (乙) | XB03XAL373E001010484733 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253815 | 20mg | Category B (乙) | XB03XAL373E001010504188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010504339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264912 | 50mg | Category B (乙) | XB03XAL373E001010504612 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20249733 | 50mg | Category B (乙) | XB03XAL373E001010505001 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253332 | 50mg | Category B (乙) | XB03XAL373E001010584106 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010604339 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20249733 | 50mg | Category B (乙) | XB03XAL373E001010605001 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010704339 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20249733 | 50mg | Category B (乙) | XB03XAL373E001010705001 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010804339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001010904339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011004339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011104339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011204339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011304339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011404339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011504339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011604339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011704339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264132 | 20mg | Category B (乙) | XB03XAL373E001011804339 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253115 | 50mg | Category B (乙) | XB03XAL373E001020100177 | NHSA |
| 广州康臣药业有限公司 | 国药准字H20253093 | 20mg | Category B (乙) | XB03XAL373E001020100400 | NHSA |
| 济川药业集团有限公司 | 国药准字H20253059 | 50mg | Category B (乙) | XB03XAL373E001020101453 | NHSA |
| 昆山龙灯瑞迪制药有限公司 | 国药准字H20255034 | 50mg | Category B (乙) | XB03XAL373E001020101533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20249732 | 20mg | Category B (乙) | XB03XAL373E001020101606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20253322 | 50mg | Category B (乙) | XB03XAL373E001020101729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20244418 | 50mg | Category B (乙) | XB03XAL373E001020102013 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20244185 | 20mg | Category B (乙) | XB03XAL373E001020102777 | NHSA |
| 哈尔滨三联药业股份有限公司 | 国药准字H20253087 | 50mg | Category B (乙) | XB03XAL373E001020103662 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20249825 | 20mg | Category B (乙) | XB03XAL373E001020104021 | NHSA |
| 上海医药集团青岛国风药业股份有限公司 | 国药准字H20264644 | 50mg | Category B (乙) | XB03XAL373E001020104034 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253816 | 50mg | Category B (乙) | XB03XAL373E001020104188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020104339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264913 | 20mg | Category B (乙) | XB03XAL373E001020104612 | NHSA |
| 浙江尖峰药业有限公司 | 国药准字H20253546 | 50mg | Category B (乙) | XB03XAL373E001020104655 | NHSA |
| 江西山香药业有限公司 | 国药准字H20249730 | 20mg | Category B (乙) | XB03XAL373E001020105345 | NHSA |
| 海口市制药厂有限公司 | 国药准字H20253575 | 50mg | Category B (乙) | XB03XAL373E001020105758 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254104 | 50mg | Category B (乙) | XB03XAL373E001020109568 | NHSA |
| 珐博进(中国)医药技术开发有限公司 | 国药准字H20180024 | 50mg | Category B (乙) | XB03XAL373E001020180523 | NHSA |
| 四川国为制药有限公司 | 国药准字H20254047 | 20mg | Category B (乙) | XB03XAL373E001020180937 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253333 | 20mg | Category B (乙) | XB03XAL373E001020184106 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264529 | 50mg | Category B (乙) | XB03XAL373E001020184221 | NHSA |
| 湖南埃威格林医药科技有限公司 | 国药准字H20255835 | 20mg | Category B (乙) | XB03XAL373E001020184441 | NHSA |
| 郑州德迈药业有限公司 | 国药准字H20255015 | 20mg | Category B (乙) | XB03XAL373E001020184733 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253115 | 50mg | Category B (乙) | XB03XAL373E001020200177 | NHSA |
| 广州康臣药业有限公司 | 国药准字H20253093 | 20mg | Category B (乙) | XB03XAL373E001020200400 | NHSA |
| 昆山龙灯瑞迪制药有限公司 | 国药准字H20255034 | 50mg | Category B (乙) | XB03XAL373E001020201533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20249732 | 20mg | Category B (乙) | XB03XAL373E001020201606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20253322 | 50mg | Category B (乙) | XB03XAL373E001020201729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20244418 | 50mg | Category B (乙) | XB03XAL373E001020202013 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20244185 | 20mg | Category B (乙) | XB03XAL373E001020202777 | NHSA |
| 哈尔滨三联药业股份有限公司 | 国药准字H20253087 | 50mg | Category B (乙) | XB03XAL373E001020203662 | NHSA |
| 齐鲁制药有限公司 | 国药准字H20249825 | 20mg | Category B (乙) | XB03XAL373E001020204021 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253816 | 50mg | Category B (乙) | XB03XAL373E001020204188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020204339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264913 | 20mg | Category B (乙) | XB03XAL373E001020204612 | NHSA |
| 江西山香药业有限公司 | 国药准字H20249730 | 20mg | Category B (乙) | XB03XAL373E001020205345 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20254104 | 50mg | Category B (乙) | XB03XAL373E001020209568 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253333 | 20mg | Category B (乙) | XB03XAL373E001020284106 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264529 | 50mg | Category B (乙) | XB03XAL373E001020284221 | NHSA |
| 湖南埃威格林医药科技有限公司 | 国药准字H20255835 | 20mg | Category B (乙) | XB03XAL373E001020284441 | NHSA |
| 郑州德迈药业有限公司 | 国药准字H20255015 | 20mg | Category B (乙) | XB03XAL373E001020284733 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253115 | 50mg | Category B (乙) | XB03XAL373E001020300177 | NHSA |
| 广州康臣药业有限公司 | 国药准字H20253093 | 20mg | Category B (乙) | XB03XAL373E001020300400 | NHSA |
| 昆山龙灯瑞迪制药有限公司 | 国药准字H20255034 | 50mg | Category B (乙) | XB03XAL373E001020301533 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20249732 | 20mg | Category B (乙) | XB03XAL373E001020301606 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20253322 | 50mg | Category B (乙) | XB03XAL373E001020301729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20244418 | 50mg | Category B (乙) | XB03XAL373E001020302013 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20244185 | 20mg | Category B (乙) | XB03XAL373E001020302777 | NHSA |
| 哈尔滨三联药业股份有限公司 | 国药准字H20253087 | 50mg | Category B (乙) | XB03XAL373E001020303662 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253816 | 50mg | Category B (乙) | XB03XAL373E001020304188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020304339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264913 | 20mg | Category B (乙) | XB03XAL373E001020304612 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253333 | 20mg | Category B (乙) | XB03XAL373E001020384106 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264529 | 50mg | Category B (乙) | XB03XAL373E001020384221 | NHSA |
| 湖南埃威格林医药科技有限公司 | 国药准字H20255835 | 20mg | Category B (乙) | XB03XAL373E001020384441 | NHSA |
| 郑州德迈药业有限公司 | 国药准字H20255015 | 20mg | Category B (乙) | XB03XAL373E001020384733 | NHSA |
| 北京福元医药股份有限公司 | 国药准字H20253115 | 50mg | Category B (乙) | XB03XAL373E001020400177 | NHSA |
| 广州康臣药业有限公司 | 国药准字H20253093 | 20mg | Category B (乙) | XB03XAL373E001020400400 | NHSA |
| 昆山龙灯瑞迪制药有限公司 | 国药准字H20255034 | 50mg | Category B (乙) | XB03XAL373E001020401533 | NHSA |
| 复星万邦(江苏)医药集团有限公司 | 国药准字H20253322 | 50mg | Category B (乙) | XB03XAL373E001020401729 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20244418 | 50mg | Category B (乙) | XB03XAL373E001020402013 | NHSA |
| 石药集团中诺药业(石家庄)有限公司 | 国药准字H20244185 | 20mg | Category B (乙) | XB03XAL373E001020402777 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253816 | 50mg | Category B (乙) | XB03XAL373E001020404188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020404339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264913 | 20mg | Category B (乙) | XB03XAL373E001020404612 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253333 | 20mg | Category B (乙) | XB03XAL373E001020484106 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20264529 | 50mg | Category B (乙) | XB03XAL373E001020484221 | NHSA |
| 山东新时代药业有限公司 | 国药准字H20253816 | 50mg | Category B (乙) | XB03XAL373E001020504188 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020504339 | NHSA |
| 浙江贝得药业有限公司 | 国药准字H20264913 | 20mg | Category B (乙) | XB03XAL373E001020504612 | NHSA |
| 湖南先施制药有限公司 | 国药准字H20253333 | 20mg | Category B (乙) | XB03XAL373E001020584106 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020604339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020704339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020804339 | NHSA |
| 安徽省先锋制药有限公司 | 国药准字H20264133 | 50mg | Category B (乙) | XB03XAL373E001020904339 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 17 filings and 9 distinct first applicants.
Generic 17
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏德源药业股份有限公司 | CYHS2503248 | Generic | 2025/09/04 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CYHS2501521 | Generic | 2025/04/23 | Not stated by source | CDE |
| 江苏诺泰澳赛诺生物制药股份有限公司 | CYHS2501520 | Generic | 2025/04/23 | Not stated by source | CDE |
| 河北紫薇山制药有限责任公司 | CYHS2601787 | Generic | 2026/07/27 | Not stated by source | CDE |
| 河北紫薇山制药有限责任公司 | CYHS2601786 | Generic | 2026/07/27 | Not stated by source | CDE |
| 芜湖道润药业有限责任公司 | CYHS2600426 | Generic | 2026/02/10 | Not stated by source | CDE |
| 芜湖道润药业有限责任公司 | CYHS2600424 | Generic | 2026/02/10 | Not stated by source | CDE |
| 天方药业有限公司 | CYHS2504096 | Generic | 2025/11/28 | Not stated by source | CDE |
| 天方药业有限公司 | CYHS2504095 | Generic | 2025/11/28 | Not stated by source | CDE |
| 珠海健福制药有限公司 | CYHS2503925 | Generic | 2025/11/12 | Not stated by source | CDE |
| 珠海健福制药有限公司 | CYHS2503924 | Generic | 2025/11/12 | Not stated by source | CDE |
| 青岛国信制药有限公司 | CYHS2503373 | Generic | 2025/09/12 | Not stated by source | CDE |
| 青岛国信制药有限公司 | CYHS2503372 | Generic | 2025/09/12 | Not stated by source | CDE |
| 杭州仟源保灵药业有限公司 | CYHS2502848 | Generic | 2025/08/06 | Not stated by source | CDE |
| 杭州仟源保灵药业有限公司 | CYHS2502847 | Generic | 2025/08/06 | Not stated by source | CDE |
| 山西同达药业有限公司 | CYHS2502066 | Generic | 2025/06/11 | Not stated by source | CDE |
| 山西同达药业有限公司 | CYHS2502065 | Generic | 2025/06/11 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 河北紫薇山制药有限责任公司 | CYHS2601787 | Generic | 2026/07/27 | Not stated by source | CDE |
| 河北紫薇山制药有限责任公司 | CYHS2601786 | Generic | 2026/07/27 | Not stated by source | CDE |
| 芜湖道润药业有限责任公司 | CYHS2600426 | Generic | 2026/02/10 | Not stated by source | CDE |
| 芜湖道润药业有限责任公司 | CYHS2600424 | Generic | 2026/02/10 | Not stated by source | CDE |
API registrations
Non-component matches: 29 companies with A status and 4 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 罗沙司他 | 云鹏医药集团有限公司 | Y20260000055 | I | Exact ingredient | 2026/02/10 | CDE |
| 罗沙司他 | 苏中药业集团股份有限公司 | Y20250000533 | I | Exact ingredient | 2025/06/04 | CDE |
| 罗沙司他 | 江苏诺泰澳赛诺生物制药股份有限公司 | Y20250000239 | A | Exact ingredient | 2026/10/14 | CDE |
| 罗沙司他 | 江西同和药业股份有限公司 | Y20240001574 | A | Exact ingredient | 2026/06/16 | CDE |
| 罗沙司他 | 汉瑞药业（荆门）有限公司 | Y20240001403 | A | Exact ingredient | 2026/09/09 | CDE |
| 罗沙司他 | 江苏德源药业股份有限公司 | Y20240001421 | A | Exact ingredient | 2026/07/21 | CDE |
| 罗沙司他 | 湖北天舒药业有限公司 | Y20240001204 | A | Exact ingredient | 2026/07/29 | CDE |
| 罗沙司他 | 安徽美诺华药物化学有限公司 | Y20240001139 | A | Exact ingredient | 2026/05/07 | CDE |
| 罗沙司他 | Tianish Laboratories Private Limited (Unit-8) | Y20240000646 | I | Exact ingredient | 2024/07/29 | CDE |
| 罗沙司他 | 浙江赛默制药有限公司 | Y20240000096 | A | Exact ingredient | 2025/09/09 | CDE |
| 罗沙司他 | 四川仁安药业有限责任公司 | Y20240000015 | A | Exact ingredient | 2026/09/12 | CDE |
| 罗沙司他 | 上海迪赛诺化学制药有限公司 | Y20230000947 | A | Exact ingredient | 2026/10/09 | CDE |
| 罗沙司他 | 四川国为制药有限公司 | Y20230001147 | A | Exact ingredient | 2026/06/18 | CDE |
| 罗沙司他 | 重庆圣华曦药业股份有限公司 | Y20230001036 | A | Exact ingredient | 2025/12/24 | CDE |
| 罗沙司他 | Dr. Reddy’s Laboratories Ltd. | Y20230000881 | A | Exact ingredient | 2025/07/29 | CDE |
| 罗沙司他 | 浙江尖峰药业有限公司 | Y20230000850 | A | Exact ingredient | 2025/10/24 | CDE |
| 罗沙司他 | 江苏正济药业股份有限公司 | Y20230000769 | A | Exact ingredient | 2026/01/15 | CDE |
| 罗沙司他 | 上海合全药业股份有限公司 | Y20230000511 | A | Exact ingredient | 2024/11/21 | CDE |
| 罗沙司他 | 重庆天地药业有限责任公司 | Y20230000487 | A | Exact ingredient | 2025/08/29 | CDE |
| 罗沙司他 | 山东新时代药业有限公司 | Y20230000551 | A | Exact ingredient | 2026/10/05 | CDE |
| 罗沙司他 | 兰西哈三联制药有限公司 | Y20230000408 | A | Exact ingredient | 2024/12/20 | CDE |
| 罗沙司他 | 湖南明瑞制药股份有限公司 | Y20220001200 | A | Exact ingredient | 2024/12/10 | CDE |
| 罗沙司他 | 济川药业集团有限公司 | Y20220001295 | A | Exact ingredient | 2025/09/11 | CDE |
| 罗沙司他 | 四川科伦药业股份有限公司 | Y20220000992 | A | Exact ingredient | 2024/09/10 | CDE |
| 罗沙司他 | 山东安弘制药有限公司 | Y20220000768 | A | Exact ingredient | 2026/06/25 | CDE |
| 罗沙司他 | 石药集团欧意药业有限公司 | Y20220000705 | A | Exact ingredient | 2025/02/15 | CDE |
| 罗沙司他 | 上药康丽（常州）药业有限公司 | Y20220000483 | A | Exact ingredient | 2024/10/08 | CDE |
| 罗沙司他 | 北京福元医药股份有限公司 | Y20210001299 | A | Exact ingredient | 2023/11/20 | CDE |
| 罗沙司他 | 徐州万邦金桥制药有限公司 | Y20210000682 | A | Exact ingredient | 2025/02/09 | CDE |
| 罗沙司他 | 江西科睿药业有限公司 | Y20210000730 | A | Exact ingredient | 2026/04/03 | CDE |
| 罗沙司他 | 徐州万邦金桥制药有限公司 | Y20210000109 | I | Exact ingredient | 2021/02/22 | CDE |
| 罗沙司他 | 四川仁安药业有限责任公司 | Y20210000003 | A | Exact ingredient | 2024/06/22 | CDE |
| 罗沙司他 | 江苏普润生物医药有限公司 | Y20200000901 | A | Exact ingredient | 2025/11/02 | CDE |
| 罗沙司他 | 珐博进（中国）医药技术开发有限公司 | Y20190000056 | A | Exact ingredient | 2024/09/26 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy